alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['Oncogenic Mutations'],"[{'ncitCode': 'C111993', 'drugName': 'Ceralasertib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 224, 'code': 'CMML', 'color': 'LightSalmon', 'name': 'Chronic Myelomonocytic Leukemia', 'mainType': {'id': None, 'name': 'Myelodysplastic/Myeloproliferative Neoplasms', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MDS/MPN', 'level': 4, 'tumorForm': 'LIQUID'}",[],[],"[{'link': 'https://journals.lww.com/hemasphere/fulltext/2022/06003/p758__inhibition_of_atr_with_ceralasertib.653.aspx', 'abstract': 'Brunner, A. et al., Abstract# P758, HemaSphere, EHA 2022.'}]","Ceralasertib is an orally available, small molecule ATR serine/threonine kinase inhibitor. There is anecdotal clinical data of response to ceralasertib in patients with chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS) harboring ZRSR2 oncogenic mutations. In the Phase IB/II (NCT03770429) study of ceralasertib in 30 patients with MDS or CMML (n=22, higher risk (HR)-MDS or CMML; n=8, lower risk (LR)-MDS), patients harboring spliceosome complex mutations (n=21 [n=4 SF3B1; n=7, SRSF2; n=6, U2AF1; n=3, ZRSR2; n=1, SRSF2; n=1 ZRSR2]) demonstrated a 4.8% (n=1) complete remission (CR) rate, a 9.5% (n=2) marrow complete remission (mCR) rate, a 62% (n=13) stable disease (SD) rate and a 24% (n=5) progressive disease (PD) rate while patients with wildtype spliceosome factors (n=9) demonstrated an 11% (n=1) mCR rate, a 44% (n=4) SD rate and 44% (n=4) PD rate (Abstract: Brunner, A. et al., Abstract# P758, HemaSphere, EHA 2022. https://journals.lww.com/hemasphere/fulltext/2022/06003/p758__inhibition_of_atr_with_ceralasertib.653.aspx). For the heme response, the patients harboring spliceosome complex mutations demonstrated a 9.5% (n=2) hematological improvement-erythroid (HI-E) rate, a 9.5% (n=2) hematological improvement-neutrophil (HI-N) rate, a 4.8% (n=1) hematological improvement-platelet (HI-P) rate and 81% (n=17) were not evaluable while patients with wildtype spliceosome factors demonstrated an 11% (n=1) HI-P rate and 89% (n=8) were not evaluable (Abstract: Brunner, A. et al., Abstract# P758, HemaSphere, EHA 2022. https://journals.lww.com/hemasphere/fulltext/2022/06003/p758__inhibition_of_atr_with_ceralasertib.653.aspx)."
['Oncogenic Mutations'],"[{'ncitCode': 'C111993', 'drugName': 'Ceralasertib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 355, 'code': 'MDS', 'color': 'LightSalmon', 'name': 'Myelodysplastic Syndromes', 'mainType': {'id': None, 'name': 'Myelodysplastic Syndromes', 'tumorForm': 'LIQUID'}, 'tissue': 'Myeloid', 'children': {}, 'parent': 'MNM', 'level': 3, 'tumorForm': 'LIQUID'}",[],[],"[{'link': 'https://journals.lww.com/hemasphere/fulltext/2022/06003/p758__inhibition_of_atr_with_ceralasertib.653.aspx', 'abstract': 'Brunner, A. et al., Abstract# P758, HemaSphere, EHA 2022.'}]","Ceralasertib is an orally available, small molecule ATR serine/threonine kinase inhibitor. There is anecdotal clinical data of response to ceralasertib in patients with chronic myelomonocytic leukemia (CMML) and myelodysplastic syndromes (MDS) harboring ZRSR2 oncogenic mutations. In the Phase IB/II (NCT03770429) study of ceralasertib in 30 patients with MDS or CMML (n=22, higher risk (HR)-MDS or CMML; n=8, lower risk (LR)-MDS), patients harboring spliceosome complex mutations (n=21 [n=4 SF3B1; n=7, SRSF2; n=6, U2AF1; n=3, ZRSR2; n=1, SRSF2; n=1 ZRSR2]) demonstrated a 4.8% (n=1) complete remission (CR) rate, a 9.5% (n=2) marrow complete remission (mCR) rate, a 62% (n=13) stable disease (SD) rate and a 24% (n=5) progressive disease (PD) rate while patients with wildtype spliceosome factors (n=9) demonstrated an 11% (n=1) mCR rate, a 44% (n=4) SD rate and 44% (n=4) PD rate (Abstract: Brunner, A. et al., Abstract# P758, HemaSphere, EHA 2022. https://journals.lww.com/hemasphere/fulltext/2022/06003/p758__inhibition_of_atr_with_ceralasertib.653.aspx). For the heme response, the patients harboring spliceosome complex mutations demonstrated a 9.5% (n=2) hematological improvement-erythroid (HI-E) rate, a 9.5% (n=2) hematological improvement-neutrophil (HI-N) rate, a 4.8% (n=1) hematological improvement-platelet (HI-P) rate and 81% (n=17) were not evaluable while patients with wildtype spliceosome factors demonstrated an 11% (n=1) HI-P rate and 89% (n=8) were not evaluable (Abstract: Brunner, A. et al., Abstract# P758, HemaSphere, EHA 2022. https://journals.lww.com/hemasphere/fulltext/2022/06003/p758__inhibition_of_atr_with_ceralasertib.653.aspx)."
